2,3 thresholds of signalling strength causes negative selection. In 25% of cases, acute lymphoblastic leukaemia (ALL) cells carry the oncogenic BCR-ABL1 tyrosine kinase (Philadelphia chromosome positive), which mimics constitutively active pre-BCR signalling 4, 5 . Current therapeutic approaches are largely focused on the development of more potent tyrosine kinase inhibitors to suppress oncogenic signalling below a minimum threshold for survival 6 . We tested the hypothesis that targeted hyperactivation-above a maximum threshold-will engage a deletional checkpoint for removal of self-reactive B cells and selectively kill ALL cells. Here we find, by testing various components of proximal pre-BCR signalling in mouse BCR-ABL1 cells, that an incremental increase of Syk tyrosine kinase activity was required and sufficient to induce cell death. Hyperactive Syk was functionally equivalent to acute activation of a self-reactive BCR on ALL cells. Despite oncogenic transformation, this basic mechanism of negative selection was still functional in ALL cells. Unlike normal pre-B cells, patientderived ALL cells express the inhibitory receptors PECAM1, CD300A and LAIR1 at high levels. Genetic studies revealed that Pecam1, Cd300a and Lair1 are critical to calibrate oncogenic signalling strength through recruitment of the inhibitory phosphatases Ptpn6 (ref. 7) and Inpp5d (ref. 8) . Using a novel small-molecule inhibitor of INPP5D (also known as SHIP1) 9 , we demonstrated that pharmacological hyperactivation of SYK and engagement of negative B-cell selection represents a promising new strategy to overcome drug resistance in human ALL.
ALL represents the most frequent type of cancer in children and is frequent in adults as well. Although outcomes for patients with ALL have greatly improved over the past four decades, ALL driven by oncogenic tyrosine kinases (BCR-ABL1 in adults and other oncogenic fusion tyrosine kinases in childhood ALL) 10 remains a clinical problem. Current efforts to improve treatment options are largely focused on the development of more potent tyrosine kinase inhibitors (TKIs). However, responses to TKIs are often short lived. Our group recently identified upregulation of the BCL6 proto-oncogene in response to TKI treatment as a major mechanism of drug resistance in Philadelphia chromosome positive (Ph 1 ) ALL
11
. Here, we propose a strategy to overcome drug resistance in ALL based on the pharmacological hyperactivation of SYK.
Pre-BCR signals are initiated from immunoreceptor tyrosine-based activation motifs (ITAMs) in the cytoplasmic tail of immunoglobulin (Ig)a (CD79A) and Igb (CD79B) signalling chains 12 , and are essential for survival and proliferation of normal pre-B cells. However, hyperactive signalling from a self-reactive pre-BCR, owing to the ubiquitous presence of self-antigen, induces negative selection and cell death 3 . Here, we observed that Ph 1 ALL cells consistently lack surface expression of ITAM-bearing Iga and Igb signalling chains (Extended Data Fig. 1a ). Seemingly in contrast to compromised Iga and Igb expression, multiple components of proximal pre-BCR signalling were activated downstream of the BCR-ABL1 tyrosine kinase (Fig. 1a ). These findings demonstrate that oncogenic BCR-ABL1 supplants ITAM-dependent signalling and mimics a constitutively active pre-BCR through engagement with its proximal signalling cascade. Besides BCR-ABL1, mimicry of BCR signalling was previously demonstrated for a number of viral oncoproteins including Epstein-Barr virus latent membrane protein 2A (LMP2A) 13 . Reconstitution of Iga expression induced strong tyrosine phosphorylation of proximal pre-BCR signalling molecules, followed by cell death (Extended Data Fig. 1b-d) . Likewise, Ph 1 ALL cells from three patients were highly sensitive to reactivation of ITAM-dependent signalling (LMP2A 13 ; Extended Data Fig. 1e , f). Interestingly, activation of ITAM signalling was toxic in leukaemic but not in normal pre-B cells (Extended Data Fig. 1b) . We therefore tested whether BCR-ABL1-and ITAMdependent activation of proximal pre-BCR signalling are mutually exclusive because both engage the same pre-BCR-associated tyrosine kinases. Consequently, we repeated activation of ITAM signalling in the presence and absence of TKI treatment (imatinib; Fig. 1b ). Seemingly paradoxically, treatment with imatinib, although designed to kill leukaemia cells, rescued BCR-ABL1 ALL cells in this experimental setting, and subsequent washout of imatinib reversed the protective effect (Fig. 1b) .
To pinpoint which aspect of proximal pre-BCR signalling is toxic to Ph 1 ALL cells, we used genetic systems for hyperactivation of Syk, Src and Btk. In contrast to Src and Btk, constitutively active Syk (Syk Myr ) induced rapid cell death (Fig. 1b and Extended Data Fig. 2a-d) . Hyperactive Syk was synthetically lethal in combination with oncogenic BCR-ABL1, and cytotoxic effects were mitigated by TKI treatment (imatinib; Fig. 1b) . Like BCR-ABL1, SYK kinase activity alone mimicked constitutively active pre-BCR signalling and was sufficient to transform mouse pro-B cells (Extended Data Fig. 2e ). Interestingly, BCR-ABL1 kinase activity induced phosphorylation of SYK at interdomain B (Fig. 1a) , which relieves the autoinhibitory conformation of Syk
14
. To study the specific function of Syk interdomain B (Y348 and Y352) tyrosines in BCR-ABL1 ALL cells, we tested loss (YRF) and phosphomimetic gain (YRE) of function mutants of Syk. Empty vectors, kinase-dead Syk(K402A) and wild-type Syk were used as controls (Fig. 1c) . In the absence of constitutive membrane localization, wild-type Syk had only minor toxic effects on ALL cells. Interestingly, however, the expression of Syk carrying phosphomimetic mutations of interdomain B tyrosines (Y348/Y352RE348/E352) induced rapid cell death (Fig. 1c) . These findings highlight the relevance of Syk interdomain B tyrosines and suggest that pharmacological approaches to increase tyrosine phosphorylation of Syk interdomain B may be useful to kill Ph 1 ALL cells. To study whether Syk tyrosine kinase activity is required for induction of cell death in pre-B ALL cells, we used a Syk tyrosine kinase inhibitor, PRT062607 (PRT). Transduction with constitutively active Syk Myr induced rapid cell death, which was rescued by pre-treatment with PRT 1 day before transduction with Syk Myr . Interestingly, a 1-day lapse of PRT treatment and transient hyperactivation of Syk was sufficient to commit pre-B ALL cells to cell death (Extended Data Fig. 1g ).
In the absence of direct strategies for Syk hyperactivation, we studied pharmacological inhibition of negative regulators of Syk. In normal pre-B cells, activation of Syk downstream of the pre-BCR is negatively regulated by inhibitory surface receptors that bear immunoreceptor tyrosine-based inhibitory (ITIM) 15 motifs in their cytoplasmic tail. A systematic screen identified 109 ITIM-bearing receptors in the human genome 16 , 62 of which are expressed in B cells. Compared to normal pre-B cells and mature B-cell lymphoma, the majority of ITIM receptors were upregulated in Ph 1 ALL cells. On the basis of the ratio of expression values in Ph 1 ALL compared to pre-B cells and mature B-cell lymphoma, PECAM1, CD300A and LAIR1 were identified as among the top-ranking ITIM receptors, which was confirmed by flow cytometry (Extended Data Fig. 3 ).
To determine whether high expression levels of ITIM-bearing receptors influence the course of human ALL, we segregated patients from two clinical trials (the Children's Oncology Group (COG) P9906 study and the Eastern Cooperative Oncology Group (ECOG) 2993 study) into two groups on the basis of whether they had higher or lower than median expression levels of PECAM1, CD300A and LAIR1 at the time of diagnosis. Higher than median expression levels of ITIM receptors on ALL cells at the time of diagnosis predicted shorter overall and relapse-free survival (Extended Data Fig. 4a-e) . These findings identify ITIM-bearing inhibitory receptors as a novel biomarker with potential use in risk stratification of children and adults with ALL.
To measure the functional consequences of ITIM-receptor deletion, pre-B cells from the bone marrow of Pecam1 2/2 and Cd300a
2/2
, as well as Lair1 fl/fl mice and wild-type controls were propagated in the presence of interleukin (Il)-7 or transformed with BCR-ABL1 to model human Ph 1 ALL. Lair1 fl/fl ALL cells were retrovirally transduced with 4-hydroxytamoxifen (4-OHT)-inducible Cre. Loss of ITIM receptors had no significant effects on the proliferation and survival of normal pre-B cells (Extended Data Fig. 5a ). In contrast, in the absence of ITIMbearing receptors, pre-B ALL cells underwent cellular senescence and cell cycle arrest and failed to form colonies ( Fig. 2a and Extended Data Fig. 5a , b) in parallel with activation of cell cycle checkpoint molecules and increased levels of cytoplasmic reactive oxygen species (ROS; Extended Data Fig. 4g, h ). Importantly, inducible Cre-mediated ablation of Lair1 surface expression (Extended Data Fig. 4f ) resulted in massive hyperactivation of Syk (Y352), Src kinases (Y416) and Erk (T202/Y204; Fig. 2b ), which promotes negative selection of autoreactive B-cell clones during early B-cell development 17 . In agreement with these findings, Cre-mediated deletion of Lair1 caused rapid cell death in vitro, remission of leukaemia in vivo and significantly prolonged survival of transplant-recipient mice (P 5 0.0003, log-rank test; Fig. 2c, d and Extended Data Fig. 5c ).
The surface receptors PECAM1, CD300A and LAIR1 attenuate pre-BCR signalling through ITIM-dependent recruitment and activation of inhibitory phosphatases (for example, PTPN6 (also known as SHP1), INPP5D) 7, 8 . For this reason, we performed experiments to determine whether Lair1 contributes to activation of Ptpn6 and Inpp5d. Consistent with a role of Lair1 in the recruitment and activation of Ptpn6 and Inpp5d, activating tyrosine phosphorylation of Ptpn6 (Y564) and Inpp5d (Y1020) was reduced by three-to fourfold upon inducible deletion of Lair1 (Extended Data Fig. 5d ). In genetic rescue experiments, we demonstrated that intact ITIM motifs in the cytoplasmic tails of Pecam1, Lair1 and Cd300a are critical for the survival of pre-B ALL cells: Pecam1
2/2 and Cd300a 2/2 pre-B cells were transduced with green fluorescent protein (GFP)-tagged vectors for reconstitution of Pecam1, Lair1 and Cd300a bearing either wild-type or mutant (YRF/ A) ITIM motifs or GFP empty vector controls, and then transformed by BCR-ABL1 (Fig. 2e-g ). Reconstitution with wild-type-ITIM Pecam1, Lair1 and Cd300a rescued survival and proliferation, whereas reconstitution with receptors carrying tyrosine-mutant ITIMs had no effect ( Fig. 2e-g ).
The phosphatases PTPN6 (ref. 7), INPP5D 8 and PTPN11 (also known as SHP2) 18 can all bind to ITIM motifs. We determined their mechanistic contribution to calibration of oncogenic signalling in a genetic rescue experiment: Lair1 fl/fl ALL cells were transduced with GFP-tagged expression vectors of constitutively active or phosphatase-inactive forms of Ptpn6, Inpp5d and Ptpn11 (Fig. 3a and Extended Data Fig. 5e ). Expression of constitutively active Inpp5d or Ptpn6, but not Ptpn11, rescued cell death after Cre-mediated deletion of Lair1. Interestingly, 
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G2015 Macmillan Publishers Limited. All rights reserved inducible deletion of Ptpn6 or Inpp5d was sufficient to cause cell death and a sharp increase of cellular ROS levels in ALL cells (Fig. 3b, 7a) . Given that phosphatases are sensitive to reversible inactivation by cysteine oxidation of their active sites 19 , we tested whether deletion of one single phosphatase triggers an ROSmediated chain reaction of phosphatase inactivation. Using antibodies against phosphatases in inactivated oxidized conformation, we found that deletion of either Ptpn6 or Inpp5d caused widespread cysteine oxidation and inactivation of multiple other phosphatases (Extended Data Fig. 7b ). Inducible ablation of Ptpn6 or Inpp5d caused increased expression of Arf and p53 cell cycle checkpoint molecules, G 0/1 cell cycle arrest and 15-to 40-fold reduced colony formation capacity (Fig. 3d, e and Extended Data Fig. 7c-e) . In an in vivo transplant experiment, inducible in vivo deletion of Ptpn6 or Inpp5d significantly reduced penetrance and extended the latency of the leukaemia ( Fig. 3f ; P , 0.0005, log-rank test). These findings reveal a novel and unexpected vulnerability and suggest that ITIM-bearing receptors and inhibitory phosphatases represent a novel class of therapeutic targets in pre-B ALL. Both PTPN6 and INPP5D attenuate ITAM-dependent pre-BCR signalling in normal pre-B cells 7, 8 . Cre-mediated depletion of Ptpn6 or Inpp5d protein resulted in strong hyperactivation of Syk (Y352; Fig. 3g, h ). While PTPN6 directly dephosphorylates ITAMs and SYK 7 , INPP5D hydrolyses the membrane anchor PIP3 and thereby inhibits formation and maintenance of ITAM-dependent signalling complexes at the cell membrane
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. Pre-treatment with PRT largely rescued cell death, demonstrating that hyperactivation of Syk is a mechanistic requirement for induction of cell death (Fig. 3i, j) .
B-lineage Ph 1 ALL and myeloid-lineage chronic myeloid leukaemia (CML) are both driven by BCR-ABL1. ) rendered leukaemia cells resistant to the effects of inducible deletion (Extended Data Fig. 10c -e). These findings support a scenario in which Ph 1 ALL cells are subject to B-cell-specific negative selection against hyperactive Syk tyrosine kinase signalling emanating from a self-reactive BCR, or its oncogenic mimic BCR-ABL1. Inducible expression of Cebpa subverts B-cell lineage commitment and raises the threshold for tyrosine kinase hyperactivation to trigger cell death. In this context, it is interesting to note that multiple genetic lesions in human pre-B ALL target transcription factors that mediate B-cell lineage commitment, including IKZF1, PAX5 and EBF1 (ref. 22) . Although their mechanistic role is not known, we propose that deletions of IKZF1, PAX5 and EBF1, like downregulation of PAX5 in the context of Cebpa expression, reduce the stringency of negative selection against hyperactive tyrosine kinase signalling.
A small-molecule inhibitor against INPP5D, 3-a-aminocholestane (3AC) 9 (Extended Data Fig. 10f ) selectively inhibited enzymatic activity of INPP5D (half-maximum inhibitory concentration (IC 50 ) , 2.5 mmol l . Treatment of patient-derived Ph 1 ALL cells with 3AC induced strong hyperactivation of SYK (Fig. 4a ). In patient-derived myeloid CML samples, baseline levels of SYK activity were very low and not responsive to 3AC treatment (Extended Data Fig. 10g ). Biochemical characterization of 3AC-mediated inhibition of 324 ± 27 324 ± 27 23 ± 6 23 ± 6 311 ± 18 311 ± 18 26 ± 5 26 ± 5 383 ± 21 383 ± 21 49 ± 9 49 ± 9
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Time ( (Fig. 4a) . Treatment of patient-derived TKI-resistant Ph 1 ALL cells with 3AC induced cell death within 4 days. Importantly, pre-treatment of Ph 1 ALL cells with PRT largely protected Ph 1 ALL cells against 3AC-induced cell death (Fig. 4b) , demonstrating that hyperactivation of SYK is required for induction of cell death. Dose-response analyses revealed that 3AC is selectively toxic for patient-derived Ph 1 ALL cells (IC 50 5 2.8 mmol l
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; n 5 5) compared to mature B-cell lymphoma (n 5 5; Extended Data Fig. 10h) . We next studied drug responses in a panel of six cases of Ph 1 ALL from patients who relapsed under TKI therapy, including three cases with global TKI resistance owing to the BCR-ABL1(T315I) mutation. As expected, treatment with imatinib had no effect in BCR-ABL1(T315I) cases (Extended Data Fig. 10i ). In contrast, 3AC induced massive cell death (.95%) in all six cases of Ph 1 ALL regardless of BCR-ABL1 mutation status (Extended Data Fig. 10i ). Likewise, treatment of NOD/SCID transplant-recipient mice carrying TKIresistant patient-derived (BCR-ABL1(T315I)) Ph 1 ALL cells with 3AC significantly prolonged overall survival (P 5 0.0002, log-rank test; Fig. 4c ) and reduced leukaemia burden (Fig. 4d) . While further studies are needed 
RESEARCH LETTER
to optimize pharmacological targeting of this pathway, these experiments identify transient hyperactivation of SYK and engagement of negative B-cell selection as a powerful new strategy to overcome drug resistance in Ph 1 ALL.
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Published online 23 March 2015. 199, 673-685 (2004 , daily intraperitoneal injection, n 5 7 per group). Overall survival of recipient mice in the two groups was compared by Kaplan-Meier analysis (P value calculated by log-rank test) (c) and leukaemia burden was measured by luciferase bioimaging (d). Tables 1  and 2) Table 3 ) were cultured in RPMI-1640 (Life Technologies) with GlutaMAX containing 20% FBS, 100 IU ml 21 penicillin and 100 mg ml 21 streptomycin at 37 uC in a humidified incubator with 5% CO 2 . All of the human xenograft cells and cell lines are mycoplasma free. Murine cell culture and BCR-ABL1 transformation. Bone marrow cells from constitutive or inducible knockout mice (for a list of genetic mouse models used in this study see Supplementary Table 4) were harvested and cultured in Iscove's modified Dulbecco's medium (IMDM; Invitrogen) with GlutaMAX containing 20% FBS, 50 mM 2-mercaptoethanol, 100 IU ml 21 penicillin, 100 mg ml 21 streptomycin in the presence of cytokines. For pre-B-cell culture, bone marrow cells were cultured in IMDM with 10 ng ml 21 recombinant mouse Il-7 (Peprotech) on OP9 stroma cells. For the ALL leukaemia model, pre-B cells were retrovirally transduced by BCR-ABL1. ALL cells generated from inducible knockout mice were retrovirally transduced with ER T2 or Cre-ER T2 virus, and puromycin selection was performed. 4-OHT was used to induce Cre-mediated gene deletion. For the CML-like leukaemia model, the myeloid-restricted protocol described previously was used 23 , which generates CML-like cells. Briefly, bone marrow cells were cultured in IMDM with recombinant mouse Il-3 (10 ng ml 21 ), Il-6 (25 ng ml
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METHODS
Patient samples and human cell lines. Patient samples (Supplementary
21
), Scf (50 ng ml 21 , PeproTech) and then transformed by BCR-ABL1 retrovirus. Cytokines were removed after BCR-ABL1 transduction. In vivo transplantation of leukaemia cells. Murine pre-B ALL cells transformed by BCR-ABL1 were transduced with firefly luciferase retrovirus, selected with blasticidin, and then transduced with ER T2 or Cre-ER T2 virus, selected with puromycin. 4-OHT was used to induce Cre-mediated gene deletion for 24 h and 1 3 10 6 viable cells were injected into sublethally irradiated (250 cGy) NOD/SCID mice via the tail vein. For human leukaemia cells, a lentiviral vector encoding firefly luciferase was used. Bioimaging of leukaemia progression in mice was performed after transplantation with an in vivo IVIS 100 bioluminescence/optical imaging system (Xenogen). Fifteen minutes before measuring the luminescence signal, D-luciferin (Promega) prepared in PBS was injected intraperitoneally at an amount of 2.5 mg for each mouse. General anaesthesia was induced by using 5% isoflurane and continued during the process with 2% isoflurane given through a nose cone. When a mouse was terminally sick, it was euthanized and bone marrow and spleen cells were collected for flow-cytometry analysis. All mouse experiments were subject to institutional approval by the University of California San Francisco Institutional Animal Care and Use Committee. Six-to eight-week-old female NOD-SCID mice were randomly allocated into each treatment group. The minimal number of mice in each group was calculated by using the 'cpower' function in R/Hmisc package. No blinding was used. Retroviral and lentiviral transduction. Retrovirus production was performed as described previously 11 . Briefly, transfections of the retroviral constructs together with pHIT60 (gag-pol) and pHIT123 (env) were performed using Lipofectamine 2000 (Invitrogen). Sodium butyrate (10 mM) was used for induction. The virus supernatant was collected, filtered through a 0.45 mm filter. For lentivirus, PCD/ NL-BH (gag-pol) and pMN-VSV-G (env) were used for virus packaging. The lentivirus was concentrated by centricon centrifugal filters from EMD Millipore. For transduction, non-tissue-culture-treated 6-well plates were coated with 50 mg ml 21 retronectin (Takara), and virus was loaded by centrifugation (2,000g, 90 min at 32 uC). Then virus was discarded and 2 3 10 6 pre-B cells were transduced per well by centrifugation at 600g for 30 min. Details of retroviral and lentiviral vectors used were provided in Supplementary Table 5 . Inhibitors. The BCR-ABL1 TKI imatinib was obtained from LC Laboratories. The INPP5D inhibitor 3AC and the Csk AS inhibitor 3-IB-PP1 were obtained from EMD Millipore. The SYK TKI PRT062607 was purchased from Selleck Chemicals LLC.
Cell viability assay. One-hundred-thousand human ALL cells were seeded in a volume of 50 ml medium in one well of a 96-well plate (BD Biosciences). Imatinib or any other inhibitor was diluted and incubated at the indicated concentration in a total volume of 100 ml medium. After 3 days, cell counting kit-8 (Dojindo Molecular Technologies) was used to determine the number of viable cells. Fold changes were calculated using baseline values of vehicle treated cells as a reference (set to 100%). Flow cytometry. Antibodies used in flow cytometry are mentioned in Supplementary Table 6 . For cell cycle analysis, the BrdU flow cytometry kit (BD Biosciences) or Click-iT EdU Flow Cytometry Assay Kit (Invitrogen) was used according to the manufacturer's instructions. For evaluation of intracellular ROS levels, ALL cells were incubated for 7 min with 1 mM 5-(and 6-)chloromethyl-29,79-dichlorodihydrofluorescein diacetate (CM-H 2 DCFDA; Invitrogen) at 37 uC for oxidation of the dye by ROS. After washing with PBS, the cells were incubated for an additional 15 min at 37 uC in PBS to allow complete deacetylation of the oxidized form of CM-H 2 DCFDA by intracellular esterases. The levels of fluorescence were then directly analysed by flow cytometry, gated on viable cells. Western blotting. CelLytic buffer (Sigma) supplemented with protease inhibitor cocktail (Roche Diagnostics) and phosphatase inhibitor cocktail set II (EMD Millipore) were used to lyse cells. Ten micrograms of protein lysates per sample were separated on mini precast gels (Bio-Rad) and transferred on nitrocellulose membranes (Bio-Rad). For the detection of proteins, primary antibodies, alkaline-phosphataseconjugated secondary antibodies and chemiluminescent substrate (Invitrogen) were used. Details of primary antibodies are shown in Supplementary Table 7 . Colony-forming assay for mouse cells. Ten-thousand BCR-ABL1-transformed ALL cells or 100,000 CML-like cells were used for this assay. Cells were resuspended in murine MethoCult medium (StemCell Technologies) and plated on dishes (3 cm in diameter) with an extra dish of water to prevent evaporation. After 7 to 14 days, colonies were counted. Senescence-associated b-galactosidase assay. This was performed on cytospin preparations as described previously 11 . DNA extraction and genotyping. Genomic DNA was extracted from mouse cells with NucleoSpin Tissue kit (MACHEREY-NAGEL) and PCR was performed by using Taq DNA polymerase (NEB). The primer sequences are provided in Supplementary Table 8 . Gene expression and clinical outcome data. Clinical outcome and gene expression microarray data were derived from the National Cancer Institute TARGET Data Matrix (ftp://caftpd.nci.nih.gov/pub/dcc_target/ALL/Phase_I/Discovery/clinical/) of the Children's Oncology Group (COG) Clinical Trial P9906 and from the ECOG Clinical Trial E2993. The end points of the clinical data include minimal residual disease (MRD) after 29 days of treatment (COG), overall survival (OS) and relapsefree survival (RFS) probability (COG and ECOG). Detailed information about the gene expression microarray data is provided in Supplementary Tables 9 and 10 . Statistical analysis. Unpaired, two-tailed Student's t-test was used to compare colony number, S-phase percentage and MFI of ITIM receptors between different groups. Two-sided Mann-Whitney Wilcoxon test was used to compare expression values between MRD 1 versus MRD 2 groups. OS or RFS probabilities were estimated using the Kaplan-Meier method. Log-rank test (two-sided) was used to compare patient survival between different groups. R package 'survival' version 2.35-8 was used for the survival analysis. In survival analysis, patients with ALL in each clinical trial (COG P9906 or ECOG E2993) were divided into two groups based on whether their expression was above or below the median level of a probeset or a gene (that is, the average of multiple probe sets for a gene). For a multiple-gene predictor (that is, a set of genes, such as in ITAM (CD79A, CD79B, IHGM) and ITIM (PECAM1, LAIR1, CD300A), the patients were split into four groups based on whether they had above or below the median expression levels of the sum of ITAM and the sum of ITIM gene expression levels: (1) 1 ALL cells (n 5 8) and non-tyrosine-kinase-driven B-cell lymphoma (n 5 4). c, Normal bone marrow mononucleated cells from bone marrow biopsies of healthy donors (n 5 3), patient-derived Ph 1 ALL (n 5 11) and nontyrosine-kinase-driven B-cell lymphoma (n 5 11) were analysed by flow cytometry for surface expression of the ITIM-bearing inhibitory receptors PECAM1, CD300A, LAIR1, BTLA, CEACAM1, CD22, FCRL2. Additional staining for CD72 and LILRB5 did not show significant differences between Ph 1 ALL cells and normal pre-B cells (data not shown). Statistical analysis of mean fluorescence intensities (MFIs) for normal pre-B cells (n 5 3), Ph 1 ALL (n 5 11) and non-tyrosine-kinase-driven B-cell lymphoma (n 5 11) showed significantly increased expression levels of PECAM1, LAIR1 and CD300A in Ph 1 ALL compared to normal pre-B cells and non-tyrosine-kinasedriven B-cell lymphoma. P values were calculated using unpaired, two-tailed Student's t-test.
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Extended Data Figure 4 | Higher than median expression levels of ITIMbearing inhibitory receptors predict poor outcomes in patients with pre-B ALL. a-c, mRNA levels for PECAM1, CD300A and LAIR1 were measured in 207 patients with paediatric ALL (COG P9906). PECAM1, CD300A and LAIR1 mRNA levels for ALL cells from 124 patients that had no detectable minimal residual disease (MRD negative; black) on day 29 in their bone marrow were compared to mRNA levels in 67 patients with positive MRD (red) at the time of bone marrow biopsy (day 29). On the basis of higher or lower than median expression levels of PECAM1, CD300A and LAIR1, patients were segregated into two groups (High, n 5 104; Low, n 5 103; plots in middle and right). Overall survival (OS; middle) and relapse-free survival (RFS; right) probabilities were estimated by Kaplan-Meier survival analyses. P values were calculated by Mann-Whitney-Wilcoxon test (left panels; MRD status) and log-rank test (middle and right panels; overall survival and relapse-free survival). d, e, ITAM-based agonists (CD79A, CD79B, IGHM) and ITIMbased inhibitors (PECAM1, CD300A, LAIR1) of pre-BCR signalling were combined into a six-gene outcome predictor based on 'ITAM' and 'ITIM' signatures and validated in two clinical trials for adults with Ph 1 ALL (ECOG E2993) and children with ALL (COG P9906). P values were calculated by log-rank test. f, Lair1 deletion was confirmed by flow cytometry. g, Expression of checkpoint molecules Arf, p53, p21 and p27 was measured by western blot in the presence and absence of Pecam1 and Cd300a and upon inducible deletion of Lair1 in BCR-ABL1 pre-B ALL cells. h, Accumulation of ROS was measured by staining with 2979-dichlorofluorescein diacetate (DCF) in BCR-ABL1 pre-B ALL cells (grey histograms for control; red for gene deletion). Data are representative of three independent experiments (f-h). Inpp5d deletion in pre-B ALL cells. a, The effects of deletion of Ptpn6 or Inpp5d on cellular ROS levels were measured by flow cytometry using DCF in BCR-ABL1 pre-B ALL cells (grey histograms for control; red for gene deletion). b, Whether ROS accumulation in response to deletion of Ptpn6 or Inpp5d results in wide-spread cysteine-oxidation and, hence, inactivation, of multiple other PTP active sites was determined by western blot using antibodies against oxidized PTP active sites. c, Protein levels of the checkpoint molecules Arf and p53 were measured by western blot in BCR-ABL1 ALL cells before (empty vector (EV)) and after (Cre) deletion of Ptpn6 and Inpp5d. Data are representative of three independent experiments (a-c). d, e, Functional readouts for inducible deletion of Ptpn6 and Inpp5d include measurement of proliferation (BrdU incorporation) (d) and colony formation capacity in methylcellulose (colony-forming unit (c.f.u.) assay) (e). BrdU assays (flow cytometry) and c.f.u. data (images from colonies on plates) are presented in Fig. 3d 2/2 and Cd300a 2/2 mice as well as age-matched wild-type controls were propagated in the presence of Il-3, Il-6 and Scf and transformed with retroviral BCR-ABL1. After 7 days, outgrowth of myeloid-lineage CML-like leukaemia was observed. One-hundred-thousand Pecam1 2/2 and Cd300a 2/2 CML-like cells as well as wild-type controls were plated in methylcellulose. Colonies were counted two weeks later (a). P values were calculated by unpaired, two-tailed Student's t-test (b). c-e, Myeloid progenitor cells from the bone marrow of Lair1 fl/fl mice were propagated in the presence of Il-3, Il-6 and Scf and transformed with retroviral BCR-ABL1. After 7 days, outgrowth of myeloid-lineage CML-like leukaemia was observed and CML-like phenotype was verified by flow cytometry using antibodies against B220/CD19 (negative) ) for 15 min, and phosphorylation of SYK was measured by western blot, using b-actin as loading control. h, Dose-response curves are shown for five patient-derived cases of ALL (LAX2, LAX9, BLQ1, BLQ5 and PDX2, red curves) and five cases of B-cell leukaemia/lymphoma (lacking an oncogenic tyrosine kinase; KARPAS-422, MHH-PREB-1, JEKO-1, MN-60 and JJN-3, grey curves). i, Dose-response curves are shown for the treatment of six patient-derived cases of Ph 1 ALL that have acquired global resistance to TKI treatment (LAX2, BLQ5, BLQ11) or partial resistance (ICN1, LAX9, PDX59). Dose-response curves for the TKI imatinib are shown in grey and for the INPP5D inhibitor 3AC in red (concentration plotted on same scale for both agents). Error bars (c-e, h-i) represent means 6 s.d. from three independent experiments.
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